Cargando…

Mixed responses to first‐line alectinib in non‐small cell lung cancer patients with rare ALK gene fusions: A case series and literature review

Anaplastic lymphoma kinase (ALK) fusion is a well‐defined biomarker for ALK tyrosine kinase inhibitors (TKIs) treatment in non‐small cell lung cancer (NSCLC). Alectinib, a second‐generation ALK‐TKI, has been shown to have significantly longer progression‐free survival (PFS) than first‐generation ALK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Mengnan, An, Zhou, Tang, Qiusu, Ma, Yutong, Yan, Junrong, Chen, Songan, Wang, Yina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500978/ https://www.ncbi.nlm.nih.gov/pubmed/34541785 http://dx.doi.org/10.1111/jcmm.16897

Ejemplares similares

Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report
por: Lin, Jieheng, et al.
Publicado: (2022)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review
por: Isaka, Yuri, et al.
Publicado: (2023)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2023)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
por: Zeng, Hao, et al.
Publicado: (2021)

Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature
por: Hsiao, Sheng-Yen, et al.
Publicado: (2021)

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016)

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
por: Sunga, Cass G. G., et al.
Publicado: (2023)

STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
por: Su, Cuiyun, et al.
Publicado: (2020)

High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report
por: Li, Yan, et al.
Publicado: (2022)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach
por: Carcereny, Enric, et al.
Publicado: (2021)

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
por: Zhu, Lucheng, et al.
Publicado: (2022)

Case Report: Rare Systemic and Aggressive ALK-Positive Histiocytosis With Recurrent Pancreatitis Treating by Alectinib
por: Li, Yanchu, et al.
Publicado: (2022)

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
por: Sivignon, Marine, et al.
Publicado: (2020)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report
por: Ning, Shangkun, et al.
Publicado: (2021)

Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report
por: Sugiyama, Keiji, et al.
Publicado: (2021)

Partial treatment response to alectinib in metastatic non-small cell lung cancer with KIDINS220-ALK fusion
por: Lei, Yanna, et al.
Publicado: (2023)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2021)

ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion
por: Gaule, Marina, et al.
Publicado: (2022)

Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
por: Gu, Xiaodong, et al.
Publicado: (2022)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu, Viola W, et al.
Publicado: (2018)

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
por: Peng, Ling, et al.
Publicado: (2021)

Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review
por: Gu, Rumeng, et al.
Publicado: (2021)

Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1‐ALK fusion
por: Yin, Qiang, et al.
Publicado: (2021)

HGG-04. Intramedullary spinal high grade glioma with ALK fusion and excellent response to targeted treatment with alectinib: case report
por: Dvir, Rina, et al.
Publicado: (2022)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
por: Deng, Ling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4e9f8op2agvm7ccbd4kdbl6i5h